CoChat

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Treatment of Idiopathic Pulmonary Fibrosis with Etanercept: An Exploratory, Placebo-controlled Trial

Raghu, Ganesh, Brown, Kevin K., Costabel, Ulrich, Cottin, Vincent, du Bois, Roland M., Lasky, Joseph A., Thomeer, Michiel, Utz, James P., Khandker, Rezaul K., McDermott, Lawrence, Fatenejad, Saeed · 2008 · American Journal of Respiratory and Critical Care Medicine

Abstract

Rationale: An efficacious medical therapy for idiopathic pulmonary fibrosis (IPF) remains elusive. Objectives: To explore the efficacy and safety of etanercept in the treatment of IPF. Methods: This was a randomized, prospective, double-blind, placebo-controlled, multicenter exploratory trial in subjects with clinically progressive IPF. Primary endpoints included changes in the percentage of predicted FVC and lung diffusing capacity for carbon monoxide corrected for hemoglobin (DlCOHb) and change in the alveolar to arterial oxygen pressure difference P(a–a)O2 at rest from baseline over 48 weeks. Measurements and Main Results: Eighty-eight subjects received subcutaneous etanercept (25 mg) or placebo twice weekly as their sole treatment for IPF. No differences in baseline demographics and disease status were detected between treatment groups; the mean time from first diagnosis was 13.6 months and mean FVC was 63.9% of predicted. At 48 weeks, no significant differences in efficacy endpoints were observed between the groups. A nonsignificant reduction in disease progression was seen in several physiologic, functional, and quality-of-life endpoints among subjects receiving etanercept. There was no difference in adverse events between treatment groups. Conclusions: In this exploratory study in patients with clinically progressive IPF, etanercept was well tolerated. Although there were no differences in the predefined endpoints, a decreased rate of disease progression was observed on several measures. Further evaluation of TNF antagonists in the treatment of IPF may be warranted. Clinical trial registered with www.clinicaltrials.gov (NCT 00063869).

Overview

Integrity signals

Registry

Crossref · 10.1164/rccm.200709-1446oc

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 50 references

Research works printed but not linked: 9

  1. 2005, Radiol Med (Torino), 109, 472
  2. 1997, Am J Pathol, 151, 1303
  3. 1993, Am J Pathol, 143, 651
  4. 2005, Chest, 128, 496S
  5. 2007, Am J Respir Crit Care Med, 176, A144
  6. 2006, Eur Respir J, 28, 767S
  7. 1981, Am Rev Respir Dis, 123, 659
  8. 2006, J Rheumatol, 33, 622
  9. 2006, J Rheumatol, 33, 1189

Cited by

See all 376

Metadata

Authors
Raghu, G., Brown, K. K., Costabel, U., Cottin, V., du Bois, R. M., Lasky, J. A., Thomeer, M., Utz, J. P., Khandker, R. K., McDermott, L., & Fatenejad, S.
Affiliations
  • University of Washington (US)
  • National Jewish Medical and Research Center, Denver, Colorado
  • Ruhrlandklinik (DE)
  • Lyon 1 Université (FR)
  • Tulane University (US)
  • Universitair Ziekenhuis Leuven (BE)
  • Mayo Clinic (US)
  • Pfizer (United States) (US)
Venue
American Journal of Respiratory and Critical Care Medicine
Published
2008-11-01
Volume
178
Issue
9
Pages
948-955
ISSN
  • 1073-449X (ISSN-L)
  • 1535-4970
OpenAlex
W2102969338
Cited by
370
References
50
Citations by year
2026: 6 · 2025: 12 · 2024: 10 · 2023: 11 · 2022: 21 · 2021: 27 · 2020: 12 · 2019: 12 · 2018: 9 · 2017: 26 · 2016: 18 · 2015: 22 · 2014: 22 · 2013: 32 · 2012: 36
FWCI
28.46
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Respiratory and Critical Care Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
  • Document Server@UHasselt (UHasselt) (submittedVersion)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
Keywords
idiopathic pulmonary fibrosis, etanercept, TNF antagonists, disease progression, forced vital capacity, diffusing capacity for carbon monoxide, alveolar-arterial oxygen difference, drug safety, quality of life
MeSH terms
Etanercept, Aged, Anti-Inflammatory Agents, Non-Steroidal, Carbon Monoxide, Double-Blind Method, Female, Humans, Immunoglobulin G, Lung, Male, Oxygen, Predictive Value of Tests, Prospective Studies, Pulmonary Fibrosis, Quality of Life, Research Design, Severity of Illness Index, Vital Capacity, Treatment Outcome, Receptors, Tumor Necrosis Factor, Disease Progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment of Idiopathic Pulmonary Fibrosis with Etanercept: An Exploratory, Placebo-controlled Trial. https://app.cochat.ai/papers/10.1164/rccm.200709-1446oc
The paper
Raghu, G., Brown, K. K., Costabel, U., Cottin, V., du Bois, R. M., Lasky, J. A., Thomeer, M., Utz, J. P., Khandker, R. K., McDermott, L., & Fatenejad, S. (2008). Treatment of Idiopathic Pulmonary Fibrosis with Etanercept: An Exploratory, Placebo-controlled Trial. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.200709-1446oc

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.